Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab versus placebo as adjuvant treatment for high-risk early-stage breast cancer
NL-OMON44657Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Apr 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Denosumab with Placebo (2 arms). Primary endpoint: Bone metastasis-free survival. Started Apr 2011; status: active, not recruiting.
02
Drugs
denosumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON44657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44657.